Literature DB >> 25027412

Frontobasal gray matter loss is associated with the TREM2 p.R47H variant.

Elkin O Luis1, Sara Ortega-Cubero2, Isabel Lamet3, Cristina Razquin4, Carlos Cruchaga5, Bruno A Benitez5, Elena Lorenzo4, Jaione Irigoyen2, Maria A Pastor6, Pau Pastor7.   

Abstract

A rare heterozygous TREM2 variant p.R47H (rs75932628) has been associated with an increased risk for Alzheimer's disease (AD). We aimed to investigate the clinical presentation, neuropsychological profile, and regional pattern of gray matter and white matter loss associated with the TREM2 variant p.R47H, and to establish which regions best differentiate p.R47H carriers from noncarriers in 2 sample sets (Spanish and Alzheimer's Disease Neuroimaging Initiative, ADNI1). This was a cross-sectional study including a total number of 16 TREM2 p.R47H carriers diagnosed with AD or mild cognitive impairment, 75 AD p.R47H noncarriers and 75 cognitively intact TREM2 p.R47H noncarriers. Spanish AD TREM2 p.R47H carriers showed apraxia (9 of 9) and psychiatric symptoms such as personality changes, anxiety, paranoia, or fears more frequently than in AD noncarriers (corrected p = 0.039). For gray matter and white matter volumetric brain magnetic resonance imaging voxelwise analyses, we used statistical parametric mapping (SPM8) based on the General Linear Model. We used 3 different design matrices with a full factorial design. Voxel-based morphometry analyses were performed separately in the 2 sample sets. The absence of interset statistical differences allowed us to perform joint and conjunction analyses. Independent voxel-based morphometry analysis of the Spanish set as well as conjunction and joint analyses revealed substantial gray matter loss in orbitofrontal cortex and anterior cingulate cortex with relative preservation of parietal lobes in AD and/or mild cognitive impairment TREM2 p.R47H carriers, suggesting that TREM2 p.R47H variant is associated with certain clinical and neuroimaging AD features in addition to the increased TREM2 p.R47H atrophy in temporal lobes as described previously. The high frequency of pathologic behavioral symptoms, combined with a preferential frontobasal gray matter cortical loss, suggests that frontobasal and temporal regions could be more susceptible to the deleterious biological effects of the TREM2 variant p.R47H.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer; Genetics; MRI; Mutation; Neuroimaging; TREM2; Variant; Voxel-based morphometry

Mesh:

Substances:

Year:  2014        PMID: 25027412      PMCID: PMC4253600          DOI: 10.1016/j.neurobiolaging.2014.06.007

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  47 in total

1.  Trail Making Test A and B: normative data stratified by age and education.

Authors:  Tom N Tombaugh
Journal:  Arch Clin Neuropsychol       Date:  2004-03       Impact factor: 2.813

2.  A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment.

Authors:  Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

3.  Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.

Authors:  Kazunari Ishii; Hiroki Sasaki; Atsushi K Kono; Naokazu Miyamoto; Tetsuya Fukuda; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-31       Impact factor: 9.236

4.  Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude.

Authors:  M Mittelbronn; K Dietz; H J Schluesener; R Meyermann
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

5.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

6.  Selective brain gray matter atrophy associated with APOE ε4 and MAPT H1 in subjects with mild cognitive impairment.

Authors:  Joaquín Goñi; Sebastián Cervantes; Gonzalo Arrondo; Isabel Lamet; Pau Pastor; María A Pastor
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

8.  Population structure and eigenanalysis.

Authors:  Nick Patterson; Alkes L Price; David Reich
Journal:  PLoS Genet       Date:  2006-12       Impact factor: 5.917

9.  Insights into TREM2 biology by network analysis of human brain gene expression data.

Authors:  Paola Forabosco; Adaikalavan Ramasamy; Daniah Trabzuni; Robert Walker; Colin Smith; Jose Bras; Adam P Levine; John Hardy; Jennifer M Pocock; Rita Guerreiro; Michael E Weale; Mina Ryten
Journal:  Neurobiol Aging       Date:  2013-07-12       Impact factor: 4.673

10.  TREM2 variants in Alzheimer's disease.

Authors:  Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

View more
  15 in total

1.  Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.

Authors:  Laura Piccio; Yuetiva Deming; Jorge L Del-Águila; Laura Ghezzi; David M Holtzman; Anne M Fagan; Chiara Fenoglio; Daniela Galimberti; Barbara Borroni; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2016-01-11       Impact factor: 17.088

2.  The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk.

Authors:  Yuetiva Deming; Fabia Filipello; Francesca Cignarella; Claudia Cantoni; Simon Hsu; Robert Mikesell; Zeran Li; Jorge L Del-Aguila; Umber Dube; Fabiana Geraldo Farias; Joseph Bradley; John Budde; Laura Ibanez; Maria Victoria Fernandez; Kaj Blennow; Henrik Zetterberg; Amanda Heslegrave; Per M Johansson; Johan Svensson; Bengt Nellgård; Alberto Lleo; Daniel Alcolea; Jordi Clarimon; Lorena Rami; José Luis Molinuevo; Marc Suárez-Calvet; Estrella Morenas-Rodríguez; Gernot Kleinberger; Michael Ewers; Oscar Harari; Christian Haass; Thomas J Brett; Bruno A Benitez; Celeste M Karch; Laura Piccio; Carlos Cruchaga
Journal:  Sci Transl Med       Date:  2019-08-14       Impact factor: 17.956

Review 3.  Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Authors:  Andrew J Saykin; Li Shen; Xiaohui Yao; Sungeun Kim; Kwangsik Nho; Shannon L Risacher; Vijay K Ramanan; Tatiana M Foroud; Kelley M Faber; Nadeem Sarwar; Leanne M Munsie; Xiaolan Hu; Holly D Soares; Steven G Potkin; Paul M Thompson; John S K Kauwe; Rima Kaddurah-Daouk; Robert C Green; Arthur W Toga; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

4.  TREM2 risk variants are associated with atypical Alzheimer's disease.

Authors:  Boram Kim; EunRan Suh; Aivi T Nguyen; Stefan Prokop; Bailey Mikytuck; Olamide A Olatunji; John L Robinson; Murray Grossman; Jeffrey S Phillips; David J Irwin; Dawn Mechanic-Hamilton; David A Wolk; John Q Trojanowski; Corey T McMillan; Vivianna M Van Deerlin; Edward B Lee
Journal:  Acta Neuropathol       Date:  2022-09-16       Impact factor: 15.887

5.  Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline.

Authors:  Jorge L Del-Aguila; Maria Victoria Fernández; Suzanne Schindler; Laura Ibanez; Yuetiva Deming; Shengmei Ma; Ben Saef; Kathleen Black; John Budde; Joanne Norton; Rachel Chasse; Oscar Harari; Alison Goate; Chengjie Xiong; John C Morris; Carlos Cruchaga
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  The Alzheimer's Disease-Associated R47H Variant of TREM2 Has an Altered Glycosylation Pattern and Protein Stability.

Authors:  Ji-Seon Park; In Jung Ji; Dong-Hou Kim; Hyun Joo An; Seung-Yong Yoon
Journal:  Front Neurosci       Date:  2017-01-18       Impact factor: 4.677

7.  Neuroimaging Feature Terminology: A Controlled Terminology for the Annotation of Brain Imaging Features.

Authors:  Anandhi Iyappan; Erfan Younesi; Alberto Redolfi; Henri Vrooman; Shashank Khanna; Giovanni B Frisoni; Martin Hofmann-Apitius
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 8.  TREM2 ectodomain and its soluble form in Alzheimer's disease.

Authors:  Jiaolong Yang; Zhihui Fu; Xingyu Zhang; Min Xiong; Lanxia Meng; Zhentao Zhang
Journal:  J Neuroinflammation       Date:  2020-07-07       Impact factor: 8.322

Review 9.  Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease.

Authors:  Sophia R L Vieira; Huw R Morris
Journal:  Front Neurol       Date:  2021-06-04       Impact factor: 4.003

Review 10.  TREM2 in Neurodegenerative Diseases.

Authors:  Taylor R Jay; Victoria E von Saucken; Gary E Landreth
Journal:  Mol Neurodegener       Date:  2017-08-02       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.